Comparison · NCT01753713-deaths
Anti-angiogenic Therapy Naive Patients vs Anti-angiogenic Therapy Patients: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Anti-angiogenic Therapy Naive Patients vs Anti-angiogenic Therapy Patients: deaths from any cause. Trial comparisons, record NCT01753713-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01753713-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0526 | 0.00935 | 0.246 | wilson | |
| Risk in group 2 | 0.143 | 0.0401 | 0.399 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0902 | -0.35 | 0.129 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.368 | 0.037 | 3.67 | log | |
| Odds ratio, group 1 over group 2 | 0.333 | 0.0271 | 4.1 | log | |
| Number needed to treat, for one fewer death from any cause on Anti-angiogenic Therapy Naive Patients than on Anti-angiogenic Therapy Patients | 11.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Anti-angiogenic Therapy Naive Patients | Patients who have progressed without anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~dovitinib: Given PO~laboratory biomarker analysis: Correlative studies | 1 | 19 | EG000 |
| Group 2 | Anti-angiogenic Therapy Patients | Patients who have progressed on anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~dovitinib: Given PO~laboratory biomarker analysis: Correlative studies | 2 | 14 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- adverse events were monitored for at least 30 days following the last dose of treatment. For this study, the maximum time following a subject was 2 years.
Source ClinicalTrials.gov
Trial
- Title
- Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
- NCT number
- NCT01753713
- Phases
- PHASE2
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- dovitinib, laboratory biomarker analysis
- Lead sponsor
- Manmeet Ahluwalia, MD
- Results first posted
- 2017-08-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01753713?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01753713-deaths